Solid tumors often provide a challenging environment for the T cells of our immune system. By reprogramming the metabolism of T cells, scientists at the VIB-KU Leuven Center for Cancer Biology and ...
Preclinical data demonstrate genetic and epigenetic reprogramming can ameliorate T cell exhaustion and enhance stem-like qualities and potency of T cells in various modalities “Our SITC presentations ...
Funding will advance RegCell's first-in-class epigenetic regulatory T-cell reprogramming platform to first-in-human clinical trials in 2025 Strategic move to a U.S.-based entity will accelerate ...
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for ...
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies ...
At the recent American Society of Hematology annual meeting, researchers presented preclinical data examining how ...
Morning Overview on MSN
Experimental mRNA therapy reverses immune-cell aging in mice
Researchers have used an experimental mRNA therapy to make old immune cells in mice behave as if they were young again, ...
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by harnessing the body's immune system to target ...
A research team led by a researcher at the Medical University of South Carolina and partnering institutions has been awarded ...
Funding includes $8.5M from an oversubscribed seed financing with up to $37.3M in non-dilutive investment from The Japan Agency for Medical Research and Development (AMED), underscoring Japan's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback